GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aurobindo Pharma Ltd

Aurobindo Pharma establishes new step-down subsidiary PT Auro Pharm Indonesia

M&A ● No Immediate Change LOW RISK
📅 Filed on BSE: 10 Jul 2026, 01:02 PM IST  ·  BSE ID: 1bbd8a41-9c2f-47d4-82e2-95d8d9fdb91c
View Original BSE Filing (PDF)
💡
In Simple Terms
Aurobindo Pharma created a new fully-owned manufacturing company in Indonesia with an initial capital of IDR 20 billion.
🤖 AI Summary
  • Aurobindo Pharma's step-down subsidiary, PT Aurogen Pharma Indonesia, incorporated PT Auro Pharm Indonesia.
  • PT Auro Pharm Indonesia is a wholly owned step-down subsidiary based in Indonesia, incorporated on July 1, 2026.
  • Initial share capital subscription for PT Auro Pharm Indonesia was IDR 20,000,000,000.
  • The new subsidiary aims to undertake manufacturing operations within Indonesia.
  • No governmental or regulatory approvals were required for the incorporation.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Initial Share Capital Subscription
IDR 20,000,000,000
Percentage of Shareholding Acquired
100%
🏢 How This Affects the Company
📈
Business Impact
The incorporation of PT Auro Pharm Indonesia expands Aurobindo Pharma's manufacturing footprint to Indonesia, potentially supporting future pharmaceutical production and market access in the region. This aligns with the company's objective to undertake manufacturing operations there.
💰
Financial Impact
The initial cash subscription of IDR 20,000,000,000 for the share capital represents a cash outflow from Aurobindo Pharma's consolidated entity. The new subsidiary has no turnover as it was recently incorporated, so no immediate revenue impact.
⚙️
Operational Impact
This establishes a new operational base for manufacturing in Indonesia under PT Auro Pharm Indonesia, broadening the company's global production capabilities.
⚠️
Risk Impact
The transaction falls within related party transactions as it is a wholly owned step-down subsidiary, however, the filing states promoters and promoter group are not interested in the transaction. This introduces no new significant risks beyond standard international business operations.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this filing.
👤
Who Is Affected
All shareholders of Aurobindo Pharma Ltd are indirectly affected as the company expands its international manufacturing footprint, utilizing IDR 20,000,000,000 of cash for the new subsidiary's capital.
🔍
Management Signal
Management intends to expand manufacturing capabilities geographically into Indonesia, indicating a strategy of international operational growth.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Future disclosures regarding PT Auro Pharm Indonesia's operational commencement in Indonesia.
Aurobindo Pharma's next quarterly results for updates on international expansion strategies.
Reports on the market development and regulatory landscape in Indonesia for pharmaceutical manufacturing.
LOW RISK The filing concerns a routine subsidiary incorporation with no stated regulatory approvals required and limited initial capital outlay.
💡 Investor Takeaway
Aurobindo Pharma's wholly owned step-down subsidiary incorporated PT Auro Pharm Indonesia in Indonesia with an initial cash capital subscription of IDR 20,000,000,000. This new entity, established July 1, 2026, is intended for manufacturing operations in Indonesia.
⚖️ Strengths & Concerns

✅ Positives

  • Establishes a new manufacturing presence in Indonesia, expanding Aurobindo Pharma's global operational footprint.
  • No governmental or regulatory approvals were required, indicating a smooth and uncomplicated incorporation process.

⚠️ Concerns

  • The newly incorporated entity, PT Auro Pharm Indonesia, has no prior turnover history, providing no immediate financial performance data.
  • The initial capital outlay of IDR 20,000,000,000 is a cash outflow for establishing a new entity with an unproven local track record.
📅 Company Track Record
Aurobindo Pharma has shown recent activity in corporate restructuring and acquisitions. On July 2, 2026, it completed the transfer of its domestic branded generics business to Auropharm. On June 30, 2026, it completed the acquisition of Lannett Company, Inc., USA. On June 25, 2026, it invested Rs. 52 lakhs for a 26% stake in Swarnaakshu Solar Power.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is the name of the new subsidiary incorporated by Aurobindo Pharma?
The new wholly owned step-down subsidiary incorporated by Aurobindo Pharma's PT Aurogen Pharma Indonesia is named PT Auro Pharm Indonesia.
What is the initial capital subscription for PT Auro Pharm Indonesia?
The initial subscription to the share capital of PT Auro Pharm Indonesia was IDR 20,000,000,000, divided into 2000 equity shares of IDR 10,000,000 each.
What is the main objective of PT Auro Pharm Indonesia?
The object of incorporation for PT Auro Pharm Indonesia is to undertake manufacturing operations in Indonesia.
When was PT Auro Pharm Indonesia incorporated?
PT Auro Pharm Indonesia was incorporated on July 1, 2026, and received approval from authorities on July 9, 2026.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.